

1 April 2021

On-Market Share Buy-Back

On 30 March 2020, leading health imaging company Pro Medicus (ASX: PME) announced the implementation of an on-market share buy-for a period of 12 months. The attached Appendix 3F confirms the finalisation of that buyback.

Also attached is an Appendix 3C to announce the commencement of a new on-market share buy-back, permitting the Company to acquire up to 10% of the ordinary shares on issue during the last 12 months. In accordance with the Corporations Act, acquisitions under the on-market buy-back cannot commence until 14 days after notice has been given to ASIC, which has now been received and the notice period elapsed.

For further information:

Dr Sam Hupert
Chief Executive Officer
Pro Medicus Limited
Ph: +613 94298800

Mr. Clayton Hatch
Company Secretary
Pro Medicus Limited
Ph: +613 94298800

For personal use only

Appendix 3F

Final share buy-back notice (except minimum holding buy-back)

Introduced 1/9/99. Origin: Appendices 7D and 7E. Amended 30/9/2001, 11/01/10

Information and documents given to ASX become ASX's property and may be made public.

Name of entity	ABN/ARSN
PRO MEDICUS LIMITED	25 006 194 752

We (the entity) give ASX the following information.

Description of buy-back

1	Type of buy-back	On market share buy-back
---	------------------	--------------------------

Details of all shares/units bought back

2	Number of shares/units bought back	Nil
3	Total consideration paid or payable for the shares/units	Nil
4	If buy-back is an on-market buy-back - highest and lowest price paid	Nil

+ See chapter 19 for defined terms.

For personal use only

Compliance statement

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.



Sign here:

(Company secretary)

Date: 1 April 2021

Print name:

Clayton Hatch

Appendix 3C

Announcement of buy-back (except minimum holding buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/9/99. Origin: Appendix 7B. Amended 13/3/2000, 30/9/2001, 11/01/10

Name of entity

ABN/ARSN

PRO MEDICUS LIMITED

25 006 194 752

We (the entity) give ASX the following information.

Information about buy-back

1	Type of buy-back	On market share buy-back
2	+Class of shares which is the subject of the buy-back (eg, ordinary/preference)	Ordinary Shares
3	Voting rights (eg, one for one)	One for one
4	Fully paid/partly paid (and if partly paid, details of how much has been paid and how much is outstanding)	Fully paid
5	Number of shares in the +class on issue	104,211,574
6	Whether shareholder approval is required for buy-back	Not required – within 10/12 limit
7	Reason for buy-back	Capital management

+ See chapter 19 for defined terms.

For personal use only

Appendix 3C
Announcement of buy-back

8 Any other information material to a shareholder's decision whether to accept the offer (eg, details of any proposed takeover bid)

None

On-market buy-back

9 Name of broker who will act on the company's behalf

Goldman Sachs Australia Pty Ltd

10 Deleted 30/9/2001.

11 If the company intends to buy back a maximum number of shares - that number

10,421,157

Note: This requires a figure to be included, not a percentage.

12 If the company intends to buy back shares within a period of time - that period of time; if the company intends that the buy-back be of unlimited duration - that intention

Commencing 1st April 2021 until 31st March 2022

13 If the company intends to buy back shares if conditions are met - those conditions

Nil

Employee share scheme buy-back

14 Number of shares proposed to be bought back

Not applicable

15 Price to be offered for shares

Not applicable

+ See chapter 19 for defined terms.

For personal use only

Selective buy-back

- 16 Name of person or description of class of person whose shares are proposed to be bought back
- 17 Number of shares proposed to be bought back
- 18 Price to be offered for shares

Equal access scheme

- 19 Percentage of shares proposed to be bought back
- 20 Total number of shares proposed to be bought back if all offers are accepted
- 21 Price to be offered for shares
- 22 *Record date for participation in offer
Cross reference: Appendix 7A, clause 9.

Compliance statement

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.



Sign here:
(Company secretary)

Date: 1 April 2021

Print name: Clayton Hatch

For personal use only